Study title:
" Kurian-B-T, Ray-W-A, Arbogast-P-G, Fuchs-D-C, Dudley-J-A, Cooper-W-O.
Dr. W.O. Cooper, Department of Pediatrics, Vanderbilt University
Medical Center, AA-0216 MCN, Nashville, TN 37232, United States
e-mail: william.cooper@vanderbilt.edu.
Effect of regulatory warnings on antidepressant prescribing for
children and adolescents.
Archives of Pediatrics and Adolescent Medicine {ARCH-PEDIATR-ADOLESC-
MED}, 2007, Vol/Iss/Pg. 161/7 (690-696), eISSN: 1538-3628, ISSN:
1072-4710.
"
" Kurian-B-T, Ray-W-A, Arbogast-P-G, Fuchs-D-C, Dudley-J-A, Cooper-W-O.
Dr. W.O. Cooper, Department of Pediatrics, Vanderbilt University
Medical Center, AA-0216 MCN, Nashville, TN 37232, United States
e-mail: william.cooper@vanderbilt.edu.
Effect of regulatory warnings on antidepr...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Nervous System Diseases
|
Brands: Please see report, Please see report, Please see report |
MAH holders: Please see report, Please see report, Please see report |
Assessment: |
Active substance: PRAZEPAM |
ATC code: N05BA14
|
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|